

Listing of the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

1 - 9. (Cancelled)

10. (Original) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of a combination of (a) a chelator specific for copper, and (b) clioquinol; wherein said combination reduces, inhibits or otherwise interferes with A β -mediated production of radical oxygen species.

11. (Original) The method of claim 10 wherein the chelator specific for copper is specific for the reduced form of copper.

12. (Cancelled)

13 - 24. (Cancelled)

25. (Original) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of a combination of (a) a chelator specific for copper, and (b) clioquinol; wherein said combination prevents formation of A β amyloid, promotes, induces or otherwise facilitates resolubilization of A β deposits, or both.

26. (Original) The method of claim 25 wherein the chelator specific for copper is specific for the reduced form of copper.

27. (Cancelled)

28 - 39. (Cancelled)

40. (Currently amended) A pharmaceutical composition for treatment of conditions caused by amyloidosis, A β -mediated ROS formation, or both, comprising (a) a chelator specific for copper, and (b) clioquinol, together with one or more pharmaceutically acceptable carriers or diluents.

41. (Original) The pharmaceutical composition of claim 40 wherein the chelator is specific for the reduced form of copper.

42. (Cancelled)

43 - 57. (Cancelled)

58. (Previously presented) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of a combination of (a) a hydrophobic derivative of a chelator specific for the reduced form of copper, and (b)

clioquinol; wherein said combination reduces, inhibits or otherwise interferes with A β -mediated production of radical oxygen species.

59. (Previously presented) The method of claim 58 wherein said chelator specific for the reduced form of copper is bathocuproine.

60. (Previously presented) A method of treating amyloidosis in a subject, said method comprising administering to said subject an effective amount of a combination of (a) a hydrophobic derivative of a chelator specific for the reduced form of copper, and (b) clioquinol; wherein said combination prevents formation of A β amyloid, promotes, induces or otherwise facilitates resolubilization of A β deposits, or both.

61. (Previously presented) The method of claim 60 wherein said chelator specific for the reduced form of copper is bathocuproine.

62. (Currently amended) A pharmaceutical composition for treatment of conditions caused by amyloidosis, A β -mediated ROS formation, or both, comprising (a) a hydrophobic derivative of a chelator specific for the reduced form of copper, and (b) clioquinol, together with one or more pharmaceutically acceptable carriers or diluents.

63. (Previously presented) The pharmaceutical composition of claim 62 wherein said chelator specific for the reduced form of copper is a bathocuproine.